-
Issue 31/2013 - CO isothermal conversion technology advances into the coal-to-gas sector
Time of Update: 2022-11-12
This technology has been successfully industrialized in the field of high-concentration CO conversion of coal-to-syngas.
This technology has been successfully industrialized in the field of high-concentration CO conversion of coal-to-syngas.
This technology has been successfully industrialized in the field of high-concentration CO conversion of coal-to-syngas.
-
Overseas New Things partnered to develop cancer vaccines, and Merck paid $250 million to Moderna
Time of Update: 2022-10-20
aspx On October 12, to promote the further development of a melanoma cancer vaccine, pharmaceutical giant Merck decided to pay $250 million to its partner Moderna.
aspx On October 12, to promote the further development of a melanoma cancer vaccine, pharmaceutical giant Merck decided to pay $250 million to its partner Moderna.
-
ESMO Pre-"Research" Newsletter Atenolizumab: New Advances in the Field of Urinary Tumors
Time of Update: 2022-09-21
Abstract number: 1742P：Phase 2 study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)Research backgroundPolyADP ribose polymerase inhibitors (PARPi) modulate immunity by activating the innate immune pathway of cGAS/STING and inducing PD-L1 expression.
-
Biogen's Aduhelm is restricted by medical insurance, and Eisai, Eli Lilly and Roche accelerate the development of Alzheimer's disease treatment
Time of Update: 2022-05-21
Eisai said in a statement that the company expects to complete a rolling submission for lecanemab through the accelerated approval pathway in the coming months, following last week's CMS decision on Aduhelm's restrictive coverage .
-
The IPO preparation team on the Sci-tech Innovation Board welcomes a pharmaceutical company again, and has repeatedly broken through the barriers
Time of Update: 2021-12-05
The prospectus shows that Baili Tianheng Pharmaceutical chose the fourth set of criteria for the Sci-tech Innovation Board for this IPO: the estimated market value is not less than RMB 3 billion, and the operating income in the most recent year is not less than RMB 300 million .
-
Blood: Use CAR T cell therapy (liso-cel) to treat relapsed/refractory CLL/SLL
Time of Update: 2021-12-01
In this study, standard or high-risk CLL/SLL patients who had been treated more than two or three times (including BTKi) received two doses of liso-cel (50×106 or 100×106 CAR+ T cells) .
-
The aggregate MDI market rebounds hopelessly
Time of Update: 2021-12-01
Supply side: limited maintenance boostSupply side: limited overhaul and boost supply side: limited overhaul and boost According to Pan Jinsong, a professor-level senior engineer at the Shandong Institute of Industry and Information Technology, entering November, as manufacturers lowered their ex-factory prices, the aggregate MDI market started a rapid decline mode.
-
J Clin Oncol: Efficacy of Ibrutinib + Rituximab vs. Placebo + Rituximab in the Treatment of Waldenstrm Macroglobulinemia: Results from the final analysis of the randomized Phase III iNNOVATE study
Time of Update: 2021-10-10
In summary, in the final analysis of the iNNOVATE study with a median follow-up of 50 months, regardless of the MYD88 or CXCR4 mutation status, previous treatment status, and patient characteristics, Ibritinib-rituximab showed superior clinical persistence Benefit .
-
Alzheimer's disease drug candidate ACD856, a new round of phase I study has started
Time of Update: 2021-10-09
Preclinical studies have shown that AlzeCure's drug candidates can enhance communication between nerve cells and improve cognitive ability, including memory function .
NeuroRestore is a candidate drug platform for symptom relief for cognitively impaired disease states, such as Alzheimer's disease, sleep apnea, traumatic brain injury and Parkinson's disease .
-
Luoxin Pharmaceutical's Cefmetazole Sodium for Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-09-28
Cefmetazole sodium is highly stable to β-lactamase, and has the same strong antibacterial activity against β-lactamase-producing and non-β-lactamase-producing sensitive bacteria .
Aspergillus also has strong antibacterial activity .
In addition, it also shows strong antibacterial effects against anaerobic bacteria such as Peptostreptococcus, Bacteroides, Prevotes (except Biloba Prevotes) and other anaerobic bacteria .
-
Nat Med: Immunogenicity and safety of CoronaVac inactivated vaccine in patients with autoimmune rheumatism: Phase 4 clinical trial
Time of Update: 2021-08-04
The main result of this clinical trial was that compared with the CG group, the ARD group had anti-SARS-CoV-2 IgG seroconversion (SC) and neutralizing antibodies (NAb) 6 weeks after the second dose (day 69 (D69)) The positive rate decreased by ≥15% .
-
The third-generation BTK inhibitor pirtobrutinib enables B-cell malignant tumors to achieve lasting remission
Time of Update: 2021-06-22
The researchers published the results of an industry-sponsored, multi-center Phase 1/2 trial of the new reversibly conjugated BTKi pirtobrutinib (LOXO-305), which included 323 cases of relapsed or refractory chronic lymphocytic leukemia/small lymphoid Patients with cell lymphoma (CLL/SLL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL) .
-
Ten construction Zhejiang Petrochemical Phase II project is at full speed
Time of Update: 2021-06-12
At present, under the hard work of the staff participating in the construction of the project department, 80% of the total construction of two 3 million tons/year slurry bed residual oil hydrogenation units has been completed, 300,000 tons/year LDPE+EVA and 400,000 tons/year Over 60% of the annual LDPE device construction tasks were completed, laying a solid foundation for the timely realization of the project’s high-standard delivery goals.
-
FDA accelerates approval of sacituzumab govitecan for the treatment of advanced urothelial cancer
Time of Update: 2021-04-24
S. Food and Drug Administration (FDA) accelerated the approval of the Trop-2 antibody conjugate sacituzumab govitecan for patients who have previously received platinum-containing chemotherapy and PD-1/PD-L1 inhibitor treatment Patients with locally advanced or metastatic urothelial cancer.
-
Heal her·Newborn | Southern Breast Cancer Diagnosis and Treatment Summit Forum was grandly held, big coffees gathered to explore hot issues in breast cancer treatment
Time of Update: 2021-04-14
Professor Chen Qianjun first pointed out that the 6-year iDFS subgroup analysis results of the APHINITY study showed that compared with the control group, the double-target adjuvant treatment with Trapa increased the 6-year DFS rate of patients with positive lymph nodes by 4.
